Gubra (GUBRA) 주식 개요
생명공학 회사인 Gubra A/S는 유럽, 북미 및 전 세계에서 대사성 및 섬유성 질환의 전임상 계약 연구와 펩타이드 기반 신약 개발에 주력하고 있습니다. 자세히 보기
GUBRA Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Gubra A/S 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | DKK 311.80 |
| 52주 최고가 | DKK 557.50 |
| 52주 최저가 | DKK 290.20 |
| 베타 | 0.31 |
| 1개월 변동 | -21.06% |
| 3개월 변동 | -7.70% |
| 1년 변동 | -26.81% |
| 3년 변동 | 190.21% |
| 5년 변동 | n/a |
| IPO 이후 변동 | 183.45% |
최근 뉴스 및 업데이트
새로운 내러티브 • Sep 04
Obesity And Metabolic Tailwinds Will Drive Powerful Long Term Upside Potential
Catalysts About Gubra Gubra focuses on peptide drug discovery, obesity and metabolic disease research, supported by an in-house CRO and venture investment platform. What are the underlying business or industry changes driving this perspective?분석 기사 • Aug 26
Analyst Forecasts For Gubra A/S (CPH:GUBRA) Are Surging Higher
Celebrations may be in order for Gubra A/S ( CPH:GUBRA ) shareholders, with the analysts delivering a significant...분석 기사 • Aug 23
Earnings Beat: Gubra A/S (CPH:GUBRA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Gubra A/S ( CPH:GUBRA ) missed earnings with its latest half-yearly results, disappointing overly-optimistic...
내러티브 업데이트 • Aug 21
GUBRA: Early Obesity Trial Progress Will Support Long Term Upside
Analysts have lifted their fair value estimate for Gubra from DKK 451.50 to DKK 501.00. They cite updated assumptions for revenue growth, profit margin and future P/E as key drivers of the higher price target.
새로운 내러티브 • Aug 21
Obesity Drug Partnerships And CRO Demand Will Support Steady Long-Term Prospects
Catalysts About Gubra Gubra is a peptide focused biotech and CRO company that develops obesity and metabolic drug candidates while providing preclinical research services to pharmaceutical and biotech clients. What are the underlying business or industry changes driving this perspective?Recent updates
새로운 내러티브 • Sep 04
Obesity And Metabolic Tailwinds Will Drive Powerful Long Term Upside Potential
Catalysts About Gubra Gubra focuses on peptide drug discovery, obesity and metabolic disease research, supported by an in-house CRO and venture investment platform. What are the underlying business or industry changes driving this perspective?분석 기사 • Aug 26
Analyst Forecasts For Gubra A/S (CPH:GUBRA) Are Surging Higher
Celebrations may be in order for Gubra A/S ( CPH:GUBRA ) shareholders, with the analysts delivering a significant...분석 기사 • Aug 23
Earnings Beat: Gubra A/S (CPH:GUBRA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Gubra A/S ( CPH:GUBRA ) missed earnings with its latest half-yearly results, disappointing overly-optimistic...내러티브 업데이트 • Aug 21
GUBRA: Early Obesity Trial Progress Will Support Long Term Upside
Analysts have lifted their fair value estimate for Gubra from DKK 451.50 to DKK 501.00. They cite updated assumptions for revenue growth, profit margin and future P/E as key drivers of the higher price target.새로운 내러티브 • Aug 21
Obesity Drug Partnerships And CRO Demand Will Support Steady Long-Term Prospects
Catalysts About Gubra Gubra is a peptide focused biotech and CRO company that develops obesity and metabolic drug candidates while providing preclinical research services to pharmaceutical and biotech clients. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Jun 24
GUBRA: Upcoming Phase 2 Obesity Milestone Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor tweaks to the discount rate and future P/E assumptions, without a shift in their overall valuation view. What's in the News for Gubra Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, a potential first in class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases, based on Gubra discovered technology.내러티브 업데이트 • Jun 10
GUBRA: Phase 2 Obesity Candidate Progress Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions. What's in the News Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, an investigational triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases.내러티브 업데이트 • May 26
GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside
Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.분석 기사 • May 14
Analysts' Revenue Estimates For Gubra A/S (CPH:GUBRA) Are Surging Higher
Gubra A/S ( CPH:GUBRA ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...내러티브 업데이트 • Apr 27
GUBRA: Obesity Trial Pipeline Will Drive Long Term Upside
Analysts have kept their DKK 469.50 price target on Gubra unchanged, citing only minor tweaks to inputs such as discount rate, revenue growth, profit margin and forward P/E assumptions, rather than any shift in their overall view. What's in the News Gubra has called its annual general meeting for March 26, 2026, with the board proposing to renew and extend its authorization to issue warrants, including an increase of 120,277 warrants and an extension of the authorization period to March 26, 2031 (Key Developments).내러티브 업데이트 • Apr 12
GUBRA: Obesity Study And Ventures Unit Will Drive Long Term Upside
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing only marginal adjustments to assumptions such as the discount rate and forward P/E as the basis for this maintained view. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy, including muscle volume and muscle function endpoints, in about 188 participants across multiple indications and patient groups (Key Developments).내러티브 업데이트 • Mar 29
GUBRA: Obesity Trial And Ventures Expansion Will Drive Future Upside Potential
Analysts have kept their DKK price target for Gubra unchanged at DKK469.50, citing essentially stable assumptions on discount rate, revenue trajectory, profit margin and forward P/E as reasons to maintain their prior valuation view. What's in the News Clinical trial application submitted in Germany for GUB-UCN2, a first in human Phase 1/2a study targeting high quality weight loss, with about 188 participants across multiple indications and patient groups, including combination use with incretin based therapy for obesity (Product Related Announcement).내러티브 업데이트 • Mar 15
GUBRA: Future Obesity Trial And Ventures Platform Will Drive Upside Potential
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing model adjustments that reflect a slightly higher discount rate, softer revenue expectations, a lower projected profit margin and a higher future P/E multiple. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study aimed at high quality weight loss, with a design that looks at safety, tolerability, pharmacokinetics, preliminary efficacy, muscle volume and muscle function in about 188 participants, including both healthy volunteers and people living with obesity, as a standalone therapy and in combination with incretin based treatment.내러티브 업데이트 • Mar 01
GUBRA: Future Pipeline Milestones And Royalties Will Drive Upside Potential
Analysts have reduced their price target for Gubra from DKK 502.50 to DKK 469.50, reflecting updated views on discount rates, revenue contraction, profit margins and a significantly lower future P/E multiple. What's in the News Gubra plans an Analyst and Investor Day event, giving the market a closer look at its business model, pipeline and long term priorities (Key Developments).내러티브 업데이트 • Aug 16
AbbVie Agreement And Clinical Trials Will Unlock New Avenues
The significant downward revision in Gubra’s consensus price target reflects lowered expectations for future growth and earnings, as evidenced by reduced forecasts for both revenue growth and the future P/E multiple, resulting in a new fair value estimate of DKK540. What's in the News Extraordinary cash dividend of DKK 1 billion (DKK 61.2 per share) approved at EGM.분석 기사 • Jun 28
Gubra A/S' (CPH:GUBRA) 35% Jump Shows Its Popularity With Investors
Gubra A/S ( CPH:GUBRA ) shares have had a really impressive month, gaining 35% after a shaky period beforehand...새로운 내러티브 • May 16
AbbVie Agreement And Clinical Trials Will Unlock New Avenues
Strategic partnerships and collaborations with top pharma companies ensure sustainable revenue streams and growth opportunities for Gubra.분석 기사 • May 04
We're Not Worried About Gubra's (CPH:GUBRA) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Mar 11
Gubra A/S' (CPH:GUBRA) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Gubra A/S ( CPH:GUBRA ) shareholders that were waiting for something to happen have been dealt a blow with a 26% share...분석 기사 • Jan 14
We're Not Very Worried About Gubra's (CPH:GUBRA) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Jun 19
Gubra A/S' (CPH:GUBRA) Shares Climb 25% But Its Business Is Yet to Catch Up
Gubra A/S ( CPH:GUBRA ) shareholders would be excited to see that the share price has had a great month, posting a 25...분석 기사 • Mar 07
Subdued Growth No Barrier To Gubra A/S (CPH:GUBRA) With Shares Advancing 60%
Despite an already strong run, Gubra A/S ( CPH:GUBRA ) shares have been powering on, with a gain of 60% in the last...주주 수익률
| GUBRA | DK Life Sciences | DK 시장 | |
|---|---|---|---|
| 7D | -0.6% | 4.4% | 0.7% |
| 1Y | -26.8% | 5.7% | -1.5% |
수익률 대 산업: GUBRA은 지난 1년 동안 5.7%의 수익을 기록한 Danish Life Sciences 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: GUBRA은 지난 1년 동안 -1.5%를 기록한 Danish 시장보다 저조한 성과를 냈습니다.
주가 변동성
| GUBRA volatility | |
|---|---|
| GUBRA Average Weekly Movement | 6.0% |
| Life Sciences Industry Average Movement | 5.7% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in DK Market | 7.2% |
| 10% least volatile stocks in DK Market | 2.2% |
안정적인 주가: GUBRA의 주가는 지난 3개월 동안 Danish 시장보다 변동성이 컸습니다.
시간에 따른 변동성: GUBRA의 주간 변동성(6%)은 지난 1년 동안 안정적이었지만 Danish 종목 중 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2008 | 330 | Markus Rohrwild | www.gubra.dk |
생명공학 회사인 Gubra A/S는 유럽, 북미 및 국제적으로 대사성 및 섬유성 질환에 대한 전임상 계약 연구와 펩타이드 기반 신약 개발에 주력하고 있습니다. 이 회사는 세 가지 부문으로 운영됩니다: 임상 전 계약 연구(CRO), 발견 및 파트너십, 구브라 그린입니다. 제약 및 생명공학 산업을 위한 대사성 및 섬유성 질환 분야의 전임상 계약 연구 및 개발 서비스를 제공할 뿐만 아니라 생체 내 약리학, 바이오마커 분석, 생물정보학, 차세대 시퀀싱, 약물동력학, 인공지능 병리학을 통한 2D 및 3D 조직학 서비스를 제공합니다.
Gubra A/S 기초 지표 요약
| GUBRA 기초 통계 | |
|---|---|
| 시가총액 | DKK 5.12b |
| 순이익 (TTM) | -DKK 182.25m |
| 매출 (TTM) | DKK 271.02m |
18.9x
주가매출비율(P/S)-28.1x
주가수익비율(P/E)GUBRA는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| GUBRA 손익계산서 (TTM) | |
|---|---|
| 매출 | DKK 271.02m |
| 매출원가 | DKK 66.97m |
| 총이익 | DKK 204.05m |
| 기타 비용 | DKK 386.30m |
| 순이익 | -DKK 182.25m |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
Mar 03, 2027
| 주당순이익(EPS) | -11.10 |
| 총이익률 | 75.29% |
| 순이익률 | -67.25% |
| 부채/자본 비율 | 0% |
GUBRA의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/18 09:43 |
| 종가 | 2026/09/18 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Gubra A/S는 3명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Rune Dahl | DNB Carnegie |
| Jesper Ilsøe | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |